NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)--Advaxis Incorporated (OTCBB:ADXS) has developed an innovative approach in targeting cancer that enables a single bioengineered Listeria monocytogenes (Lm) bacterium to simultaneously secrete two different antigen-adjuvant fusion proteins.
